Navigation Links
Cephalon Announces Strong Third Quarter Financial Results
Date:11/8/2007

dition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval, including with respect to TREANDA; manufacturing development and capabilities; market prospects for its products, including with respect to AMRIX; sales, adjusted net income and basic adjusted income per common share guidance for 2007 and 2008; and other statements regarding matters that are not historical facts, including the Company's position and expected performance in 2007 and 2008, the final resolution or outcome of the ongoing investigations by the U.S. Attorney's Office and the Office of the Connecticut Attorney General and the final amount of any settlement and/or fines related thereto, and the relative strength of the foundation for the Company's ongoing compliance efforts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermo
'/>"/>
SOURCE Cephalon, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Oct. 1, 2014  Discovery Laboratories, Inc. (Nasdaq: ... awarded a Phase II Small Business Innovation Research ... from the National Institute of Allergy and Infectious ... (NIH) to support the development of the Company,s ... countermeasure to mitigate acute and chronic/late-phase radiation-induced lung ...
(Date:10/1/2014)... -- Pfanstiehl has announced the launch of cGMP-produced, ... USA under ICH Q7 ... playing a key role in protein glycosylation.  Now, ... media supplementation with mannose can improve overall culture ... Dr. Christopher Wilcox , VP, Business Development ...
(Date:10/1/2014)... September 30, 2014 In response ... tools to address sales, training and consumer engagement ... developed innovative mobile applications to turn their clients’ ... agency’s latest customized mobile app creations, are now ... , In partnership with Toyota, StudioPMG created a ...
(Date:10/1/2014)... October 01, 2014 TeselaGen Biotechnology ... Science Foundation to expand their bioCAD/CAM software suite, which ... modify DNA. The Small Business Innovation Research Phase II ... technology under exclusive license from the Lawrence Berkeley National ... Institute , an LBNL laboratory that develops alternative fuel ...
Breaking Biology Technology:Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives SBIR Grant Valued up to $3.0 Million to Support Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization & Glycoprotein Biosynthesis 2Digital Agency Studio PMG Launches New Case Studies on Website 2TeselaGen Receives $750k NSF SBIR Phase II Award 2TeselaGen Receives $750k NSF SBIR Phase II Award 3
... Oct. 5 VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH), ... and,commercializing targeted cancer therapeutics, announced today that it ... 11, 2007 at 2:00 p.m.,Pacific Time at the ... San Francisco.,Daniel Greenleaf, VioQuest,s president and CEO, is ...
... 5 Iomai Corporation,(Nasdaq: IOMI ) today announced ... officer, will present at the Natixis,Bleichroeder Hidden Gems Conference ... presentation will begin at 2:45 p.m. Eastern Time in ... To access the live audio webcast or the subsequent ...
... Sigma-Aldrich Corporation,(Nasdaq: SIAL ), will hold ... on Wednesday, October 24, 2007, at 11:00 a.m. ... is being webcast by Thomson/CCBN and can be ... . The webcast is also being distributed ...
Cached Biology Technology:VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 2VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco 3Sigma-Aldrich Corporation's 3rd Quarter 2007 Earnings Conference Call 2
(Date:9/30/2014)... report that a new class of chemical compounds ... They have also pinpointed the relevant target enzyme, ... , Researchers led by LMU,s Professor Angelika ... Universitt Mnchen have identified a class of chemicals ... fight against malignant tumors. The compound is itself ...
(Date:9/30/2014)... face a suite of perilous threats in today,s ... and climate change, fragile coral ecosystems are disappearing ... trend, some species of corals surrounding the island ... protector in their tropical environment: coral guard-crabs. New ... Smithsonian Marine Station scientist Seabird McKeon and the ...
(Date:9/29/2014)... DC September 29, 2014 -- Plants have ... bacteria help the pants extract nutrients and defend ... pathogens from contaminating fruits and vegetables. Now, scientist ... bacteria inside of seeds; thus ensuring that sprouting ... from the University of Notre Dame, presented their ...
Breaking Biology News(10 mins):Cancer therapy: Driving cancer cells to suicide 2Smithsonian scientists discover coral's best defender against an army of sea stars 2Plants prepackage beneficial microbes in their seeds 2
... Assistant Professor of Pharmacology at LSU Health Sciences Center ... $1.2 million Research Project (RO1) grant by the National ... of Health. The 5-year grant will support his research ... brain in regulating blood pressure and the development of ...
... in Spanish . The journal " Science ... August the results of a detailed research work about the ... years. The study has been carried out with the participation ... Panama., The results obtained prove that the main concentrations of ...
... amounts of data are being generated in health care, ... these massive and unstructured data sets has proven cumbersome ... and visual analytics is helping sift through such mountains ... of a picture. The Georgia Institute of Technology ...
Cached Biology News:LSUHSC's Lazartigues awarded $1.2 million grant 2Fossil and molecular evidence reveals the history of major marine biodiversity hotspots 2Grant supports emerging field of massive data analysis and visual analytics 2Grant supports emerging field of massive data analysis and visual analytics 3Grant supports emerging field of massive data analysis and visual analytics 4
Rabbit polyclonal to ECSIT ( Abpromise for all tested applications). entrezGeneID: 51295 SwissProtID: Q96HQ7...
HAMP Immunogen: HAMP (AAH20612, 25 a.a. ~ 85 a.a) full length recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Dual adapter for phosphotyrosine and 3-phosphotyrosine and 3-phosphoinositide...
p38 MAP Kinase gamma Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: